Adjusting for covariates in non-inferiority studies with margins defined as risk differences

Pharmaceutical Statistics

Volumn 10, Issue 5, 2011, Pages 461-466

  Mohamed, Khadeeja ^a   Embleton, Andrew ^b   Cuffe, Robert L ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

binomial regression; Cochran Mantel Haenszel; identity link; non inferiority margin; odds ratio; risk difference

Indexed keywords

RALTEGRAVIR;

ACCURACY; ARTICLE; HUMAN; MEDICAL RESEARCH; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY ANALYSIS; SIMULATION; STUDY DESIGN;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG AND NARCOTIC CONTROL; EUROPE; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONALITY; LOGISTIC MODELS; MODELS, STATISTICAL; ODDS RATIO; PLACEBOS; PYRROLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED STATES;

EID: 80053550017     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.520     Document Type: Article

References (23)

1. ICH E9-Statistical principles for clinical trials (CPMP/ICH/363/96). The European Agency for the Evaluation of Medicinal Products, 1998.
2. ICH E10-Choice of control group in clinical trials (CPMP/ICH/364/96). The European Agency for the Evaluation of Medicinal Products, 2000.
3. Committee for medicinal products for human use (CHMP). Guideline on the choice of the non-inferiority margin. EMEA/CPMP/EWP/. 2158/99, 2005.
4. FDA. Draft guidance for industry on non-inferiority clinical trials. Food and Drug Administration, HHS, 2010, March 1st, 2011. Available at
5. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW,et al. Reporting of non-inferiority and equivalence randomized trials: an extension of the CONSORT statement. Journal of the American Medical Association 2006; 295: 1152-1160. (Pubitemid 43352345)
6. Fleming TR,. Current issues in non-inferiority trials. Statistics in Medicine 2008; 27: 317-332. (Pubitemid 351227869)
7. Hung HM, Wang SJ, Tsong Y, Lawrence J, O'Neill R,. Some fundamental issues with non-inferiority testing inactive controlled trials. Statistics in Medicine 2003; 22: 213-225. (Pubitemid 36163582)
8. Hung HM, Wang SJ, O'Neill R,. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biometrical Journal 2005; 47: 28-36. (Pubitemid 40390436)
9. Hung HM, Wang SJ, O'Neill R,. Issues with statistical risks for testing methods in non-inferiority trial without a placebo arm. Journal of Biopharmaceutical Statistics 2007; 17: 201-213. (Pubitemid 46423595)
10. Hung HM, Wang SJ, O'Neill R,. Challenges and regulatory experiences with non-inferiority trial design without placebo arm. Biometrical Journal 2009; 51: 324-334.
11. D'Agostino RB Sr, Massaro JM, Sullivan LM,. Non-inferiority trials: design concepts and issuesâthe encounters of academic consultants in statistics. Statistics in Medicine 2003; 22: 169-186. (Pubitemid 36163579)
12. Wangge G, Klungel OH, Roes KCB, de Boer A, Hoes AW,et al. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS ONE 2010; 5 (10): e13550.
13. Hilton JF,. Noninferiority trial designs for odds ratios and risk differences. Statistics in Medicine 2010; 29 (9): 982-993.
14. Siqueira AL, Whitehead A, Todd S,. Active-control trials with binary data: a comparison of methods for testing superiority or non-inferiority using the odds ratio. Statistics in Medicine 2008; 27: 353-370. (Pubitemid 351227872)
15. Wellek S,. Statistical methods for the analysis of two-arm non-inferiority trials with binary outcomes. Biometrical Journal 2005; 47: 48-61. (Pubitemid 40390438)
16. Moore KL, van der Laan MJ,. Covariate adjustment in randomized trials with binary outcomes: targeted maximum likelihood estimation. Statistics in Medicine 2009; 28 (1): 39-64.
17. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sol R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S,. ACCELERATEinvestigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine 2007; 357: 124-134. (Pubitemid 47057730)
18. Steigbigel RT,et al. Raltegravir with optimised background therapy for resistant HIV-1 infection. New England Journal of Medicine 2008; 359: 339-354.
19. Cooper DA,et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. New England Journal of Medicine 2008; 359: 355-365.
20. Hill A, Sabin C,. Designing and interpreting HIV non-inferiority trials in naive and experienced patients. AIDS 2008; 22: 913-921. (Pubitemid 351681499)
21. LaVange LM, Durham TA, Koch GG,. Randomization-based nonparametric methods for the analysis of multicentre trials. Statistical Methods in Medical Research 2005; 14: 281-301. (Pubitemid 40797029)
22. Sato T,. On the variance estimator for the Mantel-Haenszel risk difference. Biometrics 1989; 45: 1323-1324. (Pubitemid 20085474)
23. Koch GG, Tangen CM, Jung JW, Amara IA,. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Statistics in Medicine 1998; 17: 1863-1892. (Pubitemid 28409938)